Sign in
SAGE Stock Price, Chart, Stats & News
Sage Therapeutics, Inc.
Save
544.94M
Market cap
–
Current P/E
–
Forward P/E
SAGE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 89.54% |
Operating margin | -461.33% |
Pretax margin | -427.77% |
Net margin | -427.77% |
Effective tax rate | – |
ROA | -71.22% |
ROE | -67.10% |
D/E | 0.03x |
Interest coverage ratio | – |
SAGE valuation
P/E | – |
P/S | 7.74x |
P/B | 1.47x |
P/CF | -1.88x |
P/FCF | -1.88x |
P/OCF | -1.88x |
PEG | -0.12x |
EV multiple | -1.99x |
About
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
Similar securities
Based on sector and market capitalization
Report issue